Bristol Myers Squibb Reports Phase 2b Data for Acalabrutinib in Hepatitis C

Bristol Myers Squibb today announced Phase 2b results for acalabrutinib in patients with hepatitis C. The study demonstrated that acalabrutinib improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of hepatitis C and support the continued development of acalabrutinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.